Medical technologies

DISRUPT BTK II, a global post-market study, finds favorable 30-day outcomes for peripheral IVL in the most challenging calcified lesions, including patients with CLTI

The OMNY-AF trial evaluates safety and efficacy of the investigational OMNYPULSE™ Platform, a novel catheter that combines a large ablation area with mapping capabilities

The first prospective female-only study of coronary interventions in complex calcific disease, EMPOWER CAD aims to confirm benefits of Shockwave intravascular lithotripsy in women Co-Principal Investigator Margaret McEntegart, MD, completed enrollment during a live case at this year’s Transcatheter Cardiovascular Therapeutics (TCT) Conference in Washington D.C.

Also at TCT: Impella ECP Pivotal Study Presentation

Next-Generation Plating System combines flexibility and stability for advanced fracture care1-4* across orthopaedic procedures5,6

The new full visual range IOL*1 delivers exceptional distance vision2 and 14% smaller readable print size vs PanOptix3†. 93% of patients become free from glasses at all distances. #4‡ TECNIS Odyssey IOL offers higher tolerance to residual refractive errors, enabling surgeons to deliver consistent and reliable patient outcomes.5¶

Shockwave E8 Augments IVL’s Capabilities for Physicians Treating Peripheral Arterial Disease Above and Below the Knee

Ethicon, DePuy Synthes, Biosense Webster, Abiomed and CERENOVUS will now go by Johnson & Johnson MedTech The planned transition has no impact on the Company’s products